[go: up one dir, main page]

AR123776A1 - Construcciones de ácido nucleico para la activación simultánea de genes - Google Patents

Construcciones de ácido nucleico para la activación simultánea de genes

Info

Publication number
AR123776A1
AR123776A1 ARP210102826A ARP210102826A AR123776A1 AR 123776 A1 AR123776 A1 AR 123776A1 AR P210102826 A ARP210102826 A AR P210102826A AR P210102826 A ARP210102826 A AR P210102826A AR 123776 A1 AR123776 A1 AR 123776A1
Authority
AR
Argentina
Prior art keywords
genes
dna element
recombinase
element according
dna
Prior art date
Application number
ARP210102826A
Other languages
English (en)
Inventor
Simon Austaender
Ulrich Goepfert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR123776A1 publication Critical patent/AR123776A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/507—Recombinase

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se informan novedosas construcciones de ADN y procedimientos de uso de las mismas. La presente invención usa una disposición deliberada de promotores y genes no productivos / inactivos en las hebras codificantes y de molde de las moléculas de ADN, que se convierten en su forma activa mediante la interacción con una recombinasa específica de sitio. Más detalladamente, el elemento de ADN de acuerdo con la presente invención no es funcional con respecto a la expresión del primer y el segundo gen contenidos. Al no ser funcional con respecto a la expresión del primer y el segundo gen, el elemento de ADN de acuerdo con la invención se puede integrar en el genoma de una célula sin el riesgo de que los genes estructurales comprendidos se expresen ya directamente después de la integración. Los genes sólo se expresan una vez que una recombinasa que reconoce y es funcional con las secuencias de reconocimiento de recombinación del elemento de ADN se activa o se introduce en la célula. De este modo, se inicia una inversión de casete mediada por recombinasa (RMCI) entre la primera y la segunda secuencia de reconocimiento de recombinasa mutada en el elemento de ADN genómicamente integrado de la invención. La RMCI da como resultado una inversión de la parte del elemento de ADN de acuerdo con la invención que se localiza entre las dos secuencias de reconocimiento de recombinasa mutantes. De este modo, el primer promotor queda enlazado de forma funcional al primer gen y el segundo promotor queda enlazado de forma funcional al segundo gen. Sólo después de esto, el primer y el segundo gen se transcriben y se expresan las respectivas proteínas codificadas. Por tanto, el elemento de ADN de acuerdo con la presente invención es especialmente útil en la activación simultánea de dos genes dentro de una célula.
ARP210102826A 2020-10-15 2021-10-13 Construcciones de ácido nucleico para la activación simultánea de genes AR123776A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20202009 2020-10-15

Publications (1)

Publication Number Publication Date
AR123776A1 true AR123776A1 (es) 2023-01-11

Family

ID=72964436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102826A AR123776A1 (es) 2020-10-15 2021-10-13 Construcciones de ácido nucleico para la activación simultánea de genes

Country Status (12)

Country Link
US (1) US20220154223A1 (es)
EP (1) EP4229204A1 (es)
JP (1) JP2023546113A (es)
KR (1) KR20230085170A (es)
CN (1) CN116348607A (es)
AR (1) AR123776A1 (es)
AU (1) AU2021363098A1 (es)
CA (1) CA3197726A1 (es)
IL (1) IL302045A (es)
MX (1) MX2023004178A (es)
TW (1) TW202229558A (es)
WO (1) WO2022079082A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947700A4 (en) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
WO2024026302A2 (en) * 2022-07-26 2024-02-01 Asimov Inc. Compositions and methods for adeno-associated viral production
CN115691671A (zh) * 2022-10-31 2023-02-03 武汉希望组生物科技有限公司 一种基于三代测序的转录组嵌合体的切分方法、装置
CN120936419A (zh) * 2023-04-12 2025-11-11 思拓凡生物工艺研发有限公司 色谱系统、其用途和用于分离腺相关衣壳的方法
WO2025054007A1 (en) * 2023-09-06 2025-03-13 Shape Therapeutics Inc. Genetic elements to increase recombinant aav production

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU680921B2 (en) 1993-05-17 1997-08-14 Regents Of The University Of California, The Ribozyme gene therapy for HIV infection and AIDS
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
EP0850313B8 (en) 1995-09-08 2009-07-29 Genzyme Corporation Improved aav vectors for gene therapy
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
AU2319497A (en) 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
JPH1033175A (ja) 1996-07-24 1998-02-10 Hisamitsu Pharmaceut Co Inc 組換えアデノ随伴ウイルスベクターの製造方法
AU722375B2 (en) 1996-09-06 2000-08-03 Trustees Of The University Of Pennsylvania, The Methods using cre-lox for production of recombinant adeno-associated viruses
DE19650714A1 (de) 1996-12-06 1998-06-10 Melchner Harald Von Prof Dr Genfallen-Konstrukt zur Identifizierung und Isolierung von Genen
JP3959117B2 (ja) 1996-12-16 2007-08-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 遺伝子治療用レトロウイルスベクターの作製法
EP0946723A1 (en) 1996-12-18 1999-10-06 Targeted Genetics Corporation Recombinase-activatable aav packaging cassettes for use in the production of aav vectors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1134287A1 (en) 2000-03-08 2001-09-19 Universite De Geneve A system to control the expression of a given gene using another gene that encodes a polypeptide with recombinant activity
WO2001083797A2 (en) 2000-04-28 2001-11-08 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
WO2001090392A1 (en) * 2000-05-26 2001-11-29 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
IL154063A0 (en) 2000-07-21 2003-07-31 Us Agriculture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
WO2002040685A2 (en) 2000-11-16 2002-05-23 Cornell Research Foundation, Inc. Vectors for conditional gene inactivation
US7074611B2 (en) 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
AU2002336744A1 (en) 2002-04-04 2003-10-20 Xiao Xiao Gene expression control system and its use in recombinant virus packaging cell lines
WO2004003180A1 (en) 2002-07-01 2004-01-08 E.I. Du Pont De Nemours And Company Method of controlling gene silencing using site-specific recombination
EP1546397A4 (en) 2002-09-27 2007-10-31 Cold Spring Harbor Lab CELL BASED RNA INTERFERENCE AND ASSOCIATED METHODS AND COMPOSITIONS
PL2277996T3 (pl) 2003-05-21 2015-03-31 Genzyme Corp Sposoby wytwarzania preparatów rekombinowanych wirionów AAV zasadniczo niezawierających pustych kapsydów
US20060110390A1 (en) 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
WO2006099615A2 (en) 2005-03-16 2006-09-21 The Johns Hopkins University Adenoviral fiber exchange shuttle system
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
CN102947453A (zh) 2010-01-28 2013-02-27 费城儿童医院 用于病毒载体纯化的可扩缩生产平台和用于基因治疗中的如此纯化的病毒载体
US8852930B2 (en) 2010-02-09 2014-10-07 The Trustees Of Columbia University In The City Of New York In vivo gene regulation by the combination of knock-in-tetO sequence into the genome and tetracycline-controlled trans-suppressor (tTS) protein
DK2737071T3 (en) 2011-07-27 2017-05-08 Genethon IMPROVED BACULOVIRUS EXPRESSION SYSTEMS
US20130058871A1 (en) 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
WO2013029030A1 (en) 2011-08-24 2013-02-28 The Board Of Trustees Of The Leland Stanford Junior University New aav capsid proteins for nucleic acid transfer
HUE054087T2 (hu) 2012-04-18 2021-09-28 Childrens Hospital Philadelphia Készítmények és eljárások nagy hatékonyságú géntranszferre AAV kapszidvariánsok alkalmazásával
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
WO2015068411A1 (ja) 2013-11-05 2015-05-14 国立大学法人東北大学 遺伝子組み換え非ヒト動物
US20170354745A1 (en) 2014-10-09 2017-12-14 The Regents Of The University Of California Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
CO2018006699A2 (es) 2015-12-01 2018-09-20 Spark Therapeutics Inc Métodos escalables para producir un vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspensión sin suero adecuado para uso clínico
EP3387137B1 (en) 2015-12-11 2021-02-03 California Institute of Technology TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
US10752904B2 (en) 2016-04-26 2020-08-25 Massachusetts Institute Of Technology Extensible recombinase cascades
WO2018096356A1 (en) 2016-11-28 2018-05-31 Horizon Discovery Limited Methods for conditional gene knock-out
IL268525B2 (en) 2017-02-17 2025-05-01 Lonza Ag Mammalian cells for producing adeno-associated viruses
AU2018281306B2 (en) 2017-06-07 2025-04-17 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
WO2018229276A1 (en) 2017-06-16 2018-12-20 Universite De Strasbourg Methods to generate conditional knock-in models
MX2020000216A (es) 2017-06-30 2020-09-03 Spark Therapeutics Inc Metodos de purificacion por columna de vectores aav.
JP2020534788A (ja) 2017-08-28 2020-12-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルスカプシド変異体及びその使用方法
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines

Also Published As

Publication number Publication date
CA3197726A1 (en) 2022-04-21
AU2021363098A1 (en) 2023-05-18
IL302045A (en) 2023-06-01
JP2023546113A (ja) 2023-11-01
MX2023004178A (es) 2023-05-03
EP4229204A1 (en) 2023-08-23
US20220154223A1 (en) 2022-05-19
WO2022079082A1 (en) 2022-04-21
KR20230085170A (ko) 2023-06-13
TW202229558A (zh) 2022-08-01
CN116348607A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
AR123776A1 (es) Construcciones de ácido nucleico para la activación simultánea de genes
ATE527347T1 (de) Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
RU2020134412A (ru) Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк
RU2018122636A (ru) Стабильные клеточные линии для продуцирования ретровирусов
JP2018534937A5 (es)
MX2021012851A (es) Cepas y métodos para la producción de proteínas que contienen hemo.
CO2019014704A2 (es) Agentes potenciadores para la transfección celular mejorada y/o la producción del vector raav
CY1119905T1 (el) Ρετροϊικα οχηματα τροποποιημενης ζωνης πολυπουρινης
JP2016528894A5 (es)
WO2018192982A3 (en) METHODS OF GENERATING ADENO-ASSOCIATED VIRAL VECTORS
TW201629229A (zh) 新穎之ｃｈｏ整合位點及其用途
AR112057A1 (es) Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b
RU2019115117A (ru) Synp198, промотор для специфической экспрессии генов в ганглионарных клетках сетчатки, избирательных в отношении направления
RU2019114217A (ru) Геномная инженерия
EA202190469A1 (ru) Способы оценки интегрированных нуклеиновых кислот
RU2017121232A (ru) Плазмиды и способ получения вирусных частиц
CR20230551A (es) Virus oncolíticos para la expresión modificada del mhc
AR122500A1 (es) Ácido nucleico codón-optimizado que codifica la proteína smn1 y su uso
Sanchez-Sandoval et al. Yeast mitochondrial RNA polymerase primes mitochondrial DNA polymerase at origins of replication and promoter sequences
JPWO2021102390A5 (es)
ES2525707T3 (es) Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
CR20230268A (es) Inmunoterapia oncolítica por remodelación del microambiente tumoral
AR043889A1 (es) Secuencias reguladoras de plantas para el control selectivo de la expresion genetica
CO2021015432A2 (es) Secuencia promotora y productos y usos relacionados de la misma
AR125287A1 (es) Polipéptidos ppo tolerantes a herbicidas inhibidores de ppo y su uso